Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 79
Selected: 0
NCT IDTitle
NCT02105129A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
NCT01773018Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT04849351Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT04755075Surufatinib Hepatic Impairment Study
NCT02601274Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT04716634Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
NCT01805791A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
NCT03976856Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
NCT05015621A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
NCT05511051A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
NCT01882764HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
NCT02631642A Study of HMPL-689 in Healthy Volunteers
NCT02590952A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
NCT02320409A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)
NCT02503033A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT01955304Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects
NCT03627520A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib
NCT00655733Phase II Study of HMPL-004 in Subjects With Crohn's Disease
NCT03873532A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients
NCT04510649Surufatinib DDI With a PPI and a CYP3A Inducer
NCT02614495Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
NCT04372407A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
NCT05509699Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
NCT04923945Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
NCT03231501HMPL-813 in Treating Patients With Glioblastoma
NCT03483948Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NCT03977090Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT05277454Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT02588170Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
NCT06437353Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT01975077A Phase Ib Study of Fruquintinib in 3rd Line mCRC
NCT02314819A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)
NCT02415023A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
NCT02590965A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
NCT04755088Surufatinib Renal Impairment Study
NCT02267967Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT02601248Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT01985555Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT02374645A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
NCT04322539A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
NCT02196688Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT04169672Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
NCT02252913A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer
NCT04557397Fruquintinib CYP3A Inhibitor and Inducer Study
NCT02689752A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib
NCT02976116A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
NCT03860532Phase I Clinical Trial in Healthy Male Volunteers
NCT02691299A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer